, Tracking Stock Market Picks
Enter Symbol:
TrovaGene, Inc. (TROV) [hlAlert]

down 5.24 %

TrovaGene, Inc. (TROV) rated Outperform by Leerink Partners

Posted on: Friday,  Aug 14, 2015  10:25 AM ET by Leerink Partners

Leerink Partners rated Outperform TrovaGene, Inc. (NASDAQ: TROV) on 08/14/2015, when the stock price was $6.10. Since
then, TrovaGene, Inc. has lost 5.25% as of 01/14/2016's recent price of $5.78.
If you would have followed this Leerink Partners's recommendation on TROV, you would have lost 5.24% of your investment in 153 days.

TrovaGene, Inc. develops transrenal molecular diagnostics that addresses health problems. The company focuses on the development of tests using its patented transrenal nucleic acid technology (transrenal DNA/RNA molecular diagnostic technology). It intends to apply its proprietary transrenal DNA/RNA test platform to develop non-invasive molecular diagnostics. The company?s technology uses urine specimens and has a range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Its TrovaGene molecular diagnostics assays would provide information that will enable physicians to provide medical care for their patients. The company was formerly known as Xenomics, Inc. and changed its name to TrovaGene, Inc. on March 1, 2010. TrovaGene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Leerink Partners
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/14/2015 10:25 AM Buy
as of 8/27/2015
1 Week down  -12.42 %
1 Month down  -5.24 %
3 Months   
1 YTD down  -5.24 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy